Orient EuroPharma Co., Ltd. 4120.TWO Stock
Orient EuroPharma Co., Ltd. Price Chart
Orient EuroPharma Co., Ltd. 4120.TWO Financial and Trading Overview
Orient EuroPharma Co., Ltd. stock price | 41.5 TWD |
Previous Close | 38.6 TWD |
Open | 38.65 TWD |
Bid | 38.35 TWD x 0 |
Ask | 38.4 TWD x 0 |
Day's Range | 38.35 - 38.65 TWD |
52 Week Range | 32.4 - 41.55 TWD |
Volume | 50.97K TWD |
Avg. Volume | 79.98K TWD |
Market Cap | 3.33B TWD |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0.3 TWD |
Forward Dividend & Yield | 0.85 (2.19%) |
Ex-Dividend Date | July 18, 2022 |
1y Target Est | N/A |
4120.TWO Valuation Measures
Enterprise Value | 6.99B TWD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.70217615 |
Price/Book (mrq) | 1.087203 |
Enterprise Value/Revenue | 1.476 |
Enterprise Value/EBITDA | 450.347 |
Trading Information
Orient EuroPharma Co., Ltd. Stock Price History
Beta (5Y Monthly) | N/A |
52-Week Change | 12.86% |
S&P500 52-Week Change | 20.43% |
52 Week High | 41.55 TWD |
52 Week Low | 32.4 TWD |
50-Day Moving Average | 37.76 TWD |
200-Day Moving Average | 36.51 TWD |
4120.TWO Share Statistics
Avg. Volume (3 month) | 79.98K TWD |
Avg. Daily Volume (10-Days) | 68.9K TWD |
Shares Outstanding | 86.75M |
Float | N/A |
Short Ratio | N/A |
% Held by Insiders | 65.12% |
% Held by Institutions | 0.45% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor | 1160:1000 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -6.46% |
Operating Margin (ttm) | -3.56% |
Gross Margin | 43.50% |
EBITDA Margin | 0.32% |
Management Effectiveness
Return on Assets (ttm) | -1.019% |
Return on Equity (ttm) | -7.97% |
Income Statement
Revenue (ttm) | 4.74B TWD |
Revenue Per Share (ttm) | 54.66 TWD |
Quarterly Revenue Growth (yoy) | 0.59% |
Gross Profit (ttm) | 2.03B TWD |
EBITDA | 15.53M TWD |
Net Income Avi to Common (ttm) | -306532992 TWD |
Diluted EPS (ttm) | -3.53 |
Quarterly Earnings Growth (yoy) | 18.09% |
Balance Sheet
Total Cash (mrq) | 2.08B TWD |
Total Cash Per Share (mrq) | 23.92 TWD |
Total Debt (mrq) | 5.12B TWD |
Total Debt/Equity (mrq) | 138.2 TWD |
Current Ratio (mrq) | 1.128 |
Book Value Per Share (mrq) | 35.274 |
Cash Flow Statement
Operating Cash Flow (ttm) | -285428992 TWD |
Levered Free Cash Flow (ttm) | -275277504 TWD |
Profile of Orient EuroPharma Co., Ltd.
Country | Taiwan |
State | N/A |
City | Taipei |
Address | No. 368, Fu Hsing South Road |
ZIP | 106 |
Phone | 886 2 2755 4881 |
Website | https://www.oepgroup.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, immunology, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk and nutritional supplements under the Karihome, Babecare, and Ostricare brands; and healthcare supplements, such as thermal water for the treatment of oral and periodontal diseases under the Buccotherm name. In addition, the company offers essences, creams, lotions, eye creams, facial treatment toners, and skin repairing essences under the AGLab name; skincare oils, body lotions, and dry skin gels under the Bio-Oil name; and children skincare products under the Mister Baby brand, as well as operates ISISPHARMA, a dermatology laboratory specialized in the development and distribution of dermo-cosmetic products. Further, it engages in the research and development of Multikine, an immunotherapy drug for head and neck cancer, which is in Phase III clinical study; NC-6004, a platinum-based micelle chemotherapeutic drug that is in Phase III clinical study; ASC-J9, a molecular chemical entity drug that has completed Phase IIb clinical study for androgen receptor degradation; and 2ccPA, a derivative of phospholipid to patients with symptomatic osteoarthritis of the knee, which is in Phase I clinical trail. The company was founded in 1982 and is based in Taipei, Taiwan.
Q&A For Orient EuroPharma Co., Ltd. Stock
What is a current 4120.TWO stock price?
Orient EuroPharma Co., Ltd. 4120.TWO stock price today per share is 41.5 TWD.
How to purchase Orient EuroPharma Co., Ltd. stock?
You can buy 4120.TWO shares on the Taipei Exchange exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Orient EuroPharma Co., Ltd.?
The stock symbol or ticker of Orient EuroPharma Co., Ltd. is 4120.TWO.
Which industry does the Orient EuroPharma Co., Ltd. company belong to?
The Orient EuroPharma Co., Ltd. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Orient EuroPharma Co., Ltd. have in circulation?
The max supply of Orient EuroPharma Co., Ltd. shares is 86.75M.
What is Orient EuroPharma Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Orient EuroPharma Co., Ltd. PE Ratio is 138.33333000 now.
What was Orient EuroPharma Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Orient EuroPharma Co., Ltd. EPS is 0.3 TWD over the trailing 12 months.
Which sector does the Orient EuroPharma Co., Ltd. company belong to?
The Orient EuroPharma Co., Ltd. sector is Healthcare.